<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080638</url>
  </required_header>
  <id_info>
    <org_study_id>H-0906-046-283</org_study_id>
    <nct_id>NCT01080638</nct_id>
  </id_info>
  <brief_title>Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours
      infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST
      elevation Myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In cardiac MRI- infarct size (total late enhancement volume at day 3-7)</measure>
    <time_frame>day 3~7 after percutaneous coronary intervention</time_frame>
    <description>MRI: magnetic resonance image</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>in-hospital and after 1-months:the major adverse cardiovascular events : death, myocardial infarction, hospitalization for heart failure, myocardial ischemia, etc.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>b. major bleeding : Hemoglobin 4 or more reduction, 2-unit If you need more than two RBC transfusions, intracranial or retroperitoneal bleeding, urgent operation for bleeding complication.</measure>
    <time_frame>1 month</time_frame>
    <description>RBC: red blood cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI III flow count /myocardial blush score after PCI</measure>
    <time_frame>1 day</time_frame>
    <description>TIMI: thrombolysis in myocardial infarction PCI: percutaneous coronary intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At cardiac MRI : LV ejection fraction,LV end-systolic volume,LV end diastolic volume,regional wall motion score index</measure>
    <time_frame>1 week</time_frame>
    <description>LV: left ventricle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge, 1- month after comparing NT-proBNP</measure>
    <time_frame>1 month</time_frame>
    <description>NT-proBNP : N-terminal pro-B-Type natriuretic peptide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Angioplasty</condition>
  <arm_group>
    <arm_group_label>Abciximab IC bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abciximab IV bolus and 12hr continuous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glycoprotein IIb/IIIa inhibitor (abciximab)</intervention_name>
    <description>patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)</description>
    <arm_group_label>Abciximab IC bolus</arm_group_label>
    <arm_group_label>Abciximab IV bolus and 12hr continuous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-ST segment elevation acute myocardial infarction

          -  within 48 hours presence of chest pain

          -  Troponin-T or I positive before CAG

          -  First myocardial infarction

          -  will be performed coronary angioplasty

        Exclusion Criteria:

          -  under 18 years of age,80 years or older

          -  Bleeding tendency

          -  History of major surgery within 4 weeks

          -  Major stroke within 2 years

          -  Thrombocytopenia (&lt;120,000 / uL)

          -  Cardiogenic shock

          -  Known allergy to aspirin, heparin, or abciximab

          -  Contraindication of MRI at study entry (implanted pacemakers, defibrillators,
             intracranial metallic implants etc)

          -  Chronic atrial fibrillation

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun-Jae Kang, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Assistant professor, Cardiology, Department of internal medicine,Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myung-Ki Seo, MD</last_name>
    <phone>82-2-2072-3757</phone>
    <email>clotinab@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun-Jae Kang, Prof</last_name>
    <phone>82-2-2072-2279</phone>
    <email>nowkang@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ki Seo, MD</last_name>
      <phone>82-2-2072-3757</phone>
      <email>clotinab@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hyun-Jae Kang, Prof</last_name>
      <phone>82-2-2072-2279</phone>
      <email>nowkang@snu.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>March 2, 2010</last_update_submitted>
  <last_update_submitted_qc>March 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo Kim/ Prof</name_title>
    <organization>Director of Cardiac Catheterization Laboratory &amp; Coronary Intervention of Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>abciximab</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>angioplasty</keyword>
  <keyword>Platelet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
    <mesh_term>Abciximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

